With Cerebral in the spotlight, DOJ, regulators to ramp up scrutiny of telehealth startups, former prosecutor says How Pfizer CEO Bourla’s evening call brought Biohaven back into the M&A fold The top biotech hubs in 2022 Sponsored: Decentralized clinical trials, patient experience and the role of supply chain management Biotech’s women leaders decry US abortion ban: ‘We will not stand by silently’ Orchestra BioMed cues up Medtronic partnership, $400M SPAC deal Reflecting on Pride Month, industry leaders see progress—and persistent challenges—for better LGBTQIA+ healthcare GSK's consumer health spinoff Haleon will launch with 'significant' debt under its belt: report Novartis UK teams up with Medtronic, others to support digital cardiovascular disease startups Vertex's Type 1 diabetes cell therapy heads back to clinic after FDA hold lifted Gun-shy on accelerated approvals, FDA will convene a 2nd expert panel meeting to reconsider Amylyx’s ALS candidate Oscar Health adds technology to personalize and improve member engagement Ra Medical notches FDA catheter clearance amid mass layoffs, potential restructuring High times: Anebulo drug reduces cannabinoid intoxication in phase 2 study Featured Story | By Heather Landi In the wake of DOJ and FTC investigations into Cerebral, U.S. regulators will ramp up their scrutiny of other telehealth companies, a former federal prosecutor says. Meanwhile, mental health experts are increasingly concerned about online mental health companies' practices and the quality of patient care. read more |
| |
|---|
|
Top Stories By Angus Liu After a call from Pfizer CEO Albert Bourla to Biohaven's chief exec Vlad Coric, Pfizer and Biohaven quickly came to terms on the buyout, reviving a plan Biohaven had explored years ago. read more By Annalee Armstrong It’s a tough time for biotech. A market correction underway. Layoffs have beset the sector. And funding as well as M&A are down across the board. But that doesn’t mean there isn’t plenty going on in labs around the country. We recap the top biotech hubs across the U.S. read more Sponsored By: Parexel The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics. read more By Annalee Armstrong More than 70 women in biotech are lending their voices to the outcry of opposition to the Supreme Court’s decision to strike down Roe v. Wade, casting reproductive rights for women and pregnant people into doubt around the nation. read more By Andrea Park True to its name, Orchestra BioMed is conducting a symphony of several business ventures at once. read more By Anastassia Gliadkovskaya The country celebrated Pride during the month of June as numerous regulations were proposed or passed striking down access to lifesaving care, from abortion to hormone therapy. As the LGBTQ+ community faces persistent barriers and new threats to healthcare access, some industry leaders tout progress with the expansion of virtual care and more support for fertility care and family building. read more By Zoey Becker GSK's consumer health spinoff will launch on July 18 with more than a portfolio of popular products. The company will have 10.3 billion pounds of debt under its belt upon launch, according to a report. read more By Conor Hale To tackle the major risk factors of heart attacks and stroke, Novartis' U.K. division is teaming up with Medtronic, RYSE Asset Management and the Chelsea and Westminster Hospital NHS Foundation Trust. read more By Max Bayer Vertex is restarting the engine of the phase 1/2 trial of its Type 1 diabetes med after the FDA lifted a clinical hold placed in May. The trial was originally paused after the agency said it didn't have enough evidence to support dose escalation. read more By Kevin Dunleavy On Tuesday, the FDA took the unusual step of announcing a second advisory committee meeting to discuss the merits and risks of Amylyx's amyotrophic lateral sclerosis drug AMX0035. The meeting is set for September 7, three weeks before an approval decision is due. read more By Cameron Evans The prioritization technology identifies opportunities at the individual level and from there, determines personalized steps for users. read more By Andrea Park Amid a rocky few months for Ra Medical Systems, the devicemaker has notched a small win, courtesy of the FDA. read more By James Waldron Cannabis has long been used as a form of self-medication, but what happens when use of that drug requires medication itself? Anebulo Pharmaceuticals hopes to be the first to answer that, as the biotech unveils positive phase 2 data for its treatment of acute cannabinoid intoxication. read more | | On Demand Webinar: Automating Cell Therapy Product Now Available on Demand The major key cost drivers of the autologous CAR T-cell therapy are generally QC analytics and biocharacterization of viral vector and supporting starting biomaterials, all of which could be developed and managed in-house. The cost and impacts revealed through the decision-making process emphasize the need for automation. Watch now to learn more. |
|---|
Resources Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 